An open clinical trial of naltrexone for amphetamine dependence: Compliance and tolerability

Nordic Journal of Psychiatry

Volumn 59, Issue 3, 2005, Pages 167-171

  Jayaram Lindström, Nitya ^a   Wennberg, Peter ^a   Beck, Olof ^a   Franck, Johan ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Amphetamine dependence; Compliance; Naltrexone; Tolerability

Indexed keywords

AMPHETAMINE; NALTREXOL; NALTREXONE; 6 BETA HYDROXYNALTREXONE; 6 BETA-HYDROXYNALTREXONE; DRUG DERIVATIVE; NARCOTIC ANTAGONIST;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; HEADACHE; HUMAN; LIVER TOXICITY; MALE; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; RELAPSE; SELF REPORT; ADOLESCENT; DRUG ABUSE; MIDDLE AGED; RECURRENT DISEASE; URINE;

ADOLESCENT; ADULT; AGED; AMPHETAMINE-RELATED DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PATIENT COMPLIANCE; RECURRENCE;

EID: 21744433171     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.1080/08039480510023052     Document Type: Article

References (15)

1. CAN (1999). Drogutvecklingen i Sverige, rapport 99. Rapport nr 8. Folkhälsoinstitutet: Centralförbundet för alkohol och narkotikaupplysning. Stockholm, 1999 [The development of drug use in Sweden, report 99].
2. CAN (2001). Drogutvecklingen i Sverige, rapport 99. Rapport nr10. Folkhälsoinstitutet: Centralförbundet för Alkohol och Narkotikaupplysning. Stockholm, 1999 [The development of drug use in Sweden, report 2001].
3. Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P. Treatment for amphetamine dependence and abuse. Cochrane Review. The Cochrane Library Oxford: Update Software, 2001: 4.
4. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49:876-80.
5. Oslin DW, Pettinati HM, Volpicelli JR, Wolf AL, Kampman KM, O'Brien CP. The effects of naltrexone on alcohol and cocaine use in dually addicted patients. J Subst Abuse Treat 1999;16:163-7.
6. Schmitz JM, Stotts AL, Rhoades HM, Grabowski J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav 2001:26:167-80.
7. Jones DN, Holtzman SG. Interaction between opioid antagonists and amphetamine: Evidence for mediation by central delta opioid receptors. J Pharmacol Exp Ther 1992;262:638-45.
8. Trujillo KA, Belluzzi JD, Stein L. Naloxone suppression of self-stimulation is independent of response difficulty. Pharmacol Biochem Behav 1989;33:147-55.
9. Trujillo KA, Belluzzi JD, Stein L. Naloxone blockade of amphetamine place preference conditioning. Psychopharmacology (Berl) 1991;104:265-74.
10. Jayaram-Lindström N, Wennberg P, Hurd YL, Franck J. Effect of naltrexone on the subjective response to amphetamine in healthy volunteers. J Clin Psychopharmacol 2004;6:665-9.
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition. Washington DC: American Psychiatric Association; 1994.
12. McLellan AT, Kushner H, Metzger D, Peters F, Smith L, Grissom G, Pettinati H, Argeriou M. The fifth edition of the Addiction Severity index. J Subst Abuse Treat 1992;9:199-213.
13. Sobell LC, Sobell MB. Time Line Follow Back. A technique for assessing self reported alcohol consumption. Measuring alcohol consumption. Toronto: Humana Press; 1992. p. 44-72.
14. Caroll K. Manual of cognitive behaviour therapy for treating cocaine addiction. National Institute of Drug Abuse. Rockville, MD: NIH Publication; 1998.
15. Hurd YL, Ungerstedt U. In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur J Pharmacol 1989;166:251-60.